FAST-ACTING INSULIN ASPART AT HIGH DOSES IN INDIVIDUALS WITH TYPE 2 DIABETES

被引：0
|
作者：
Bowering, K. [1 ]
Harvey, J. [2 ]
Kolaczynski, J. [3 ]
Snyder, J. [4 ]
Bode, B. [5 ]
机构：
[1] Univ Alberta, Div Endocrinol & Metab, Edmonton, AB, Canada
[2] Bangor Univ, Wrexham Acad Unit, Bangor, Gwynedd, Wales
[3] Novo Nordisk Inc, Clin Dev Diabet & Obes, Plainsboro, NJ USA
[4] Novo Nordisk Inc, Clin Dev Med & Regulatory Affairs, Plainsboro, NJ USA
[5] Atlanta Diabet Associates, Atlanta, GA USA
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
303
引用
收藏
页码：A133 / A133
页数：1
相关论文
共 50 条
  • [41] The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective
    Leelarathna, Lalantha
    Ashley, Donna
    Fidler, Carrie
    Parekh, Witesh
    [J]. THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2018, 9 (07) : 187 - 197
  • [42] Greater early postprandial suppression of endogenous glucose production is achieved with fast-acting insulin aspart compared to insulin aspart
    Pieber, T. R.
    Basu, A.
    Hansen, A. K.
    Sach-Friedl, S.
    Thomsen, K. M. D.
    Basu, R.
    Haahr, H.
    [J]. DIABETOLOGIA, 2017, 60 : S315 - S315
  • [43] Efficacy and safety of fast-acting insulin aspart are maintained over 52 weeks: Comparison with insulin aspart in onset 1
    Twigg, Stephen
    Mathieu, Chantal
    Bode, Bruce
    Franek, Edward
    Philis-Tsimikas, Athena
    Rose, Ludger
    Graungaard, Tina
    Osterskov, Anne Birk
    Russell-Jones, David
    [J]. CLINICAL ENDOCRINOLOGY, 2018, 89 : 63 - 63
  • [44] Efficacy and safety of fast-acting insulin aspart are maintained over 52 weeks: comparison with insulin aspart in onset 1
    Mathieu, C.
    Bode, B.
    Franek, E.
    Philis-Tsimikas, A.
    Rose, L.
    Graungaard, T.
    Osterskov, A.
    Russell-Jones, D.
    [J]. DIABETOLOGIA, 2017, 60 : S314 - S314
  • [45] Efficacy and Safety of Fast-Acting Insulin Aspart Are Maintained over 52 Weeks: Comparison with Insulin Aspart in Onset 1
    Mathieu, Chantal
    Bode, Bruce W.
    Franek, Edward
    Philis-Tsimikas, Athena
    Rose, Ludger
    Graungaard, Tina
    Osterskov, Anne Birk
    Russell-Jones, David
    [J]. DIABETES, 2017, 66 : A258 - A258
  • [46] ONSET 1: EFFICACY AND SAFETY OF MEALTIME FAST-ACTING INSULIN ASPART VERSUS INSULIN ASPART AFTER 52 WEEKS
    Bode, B.
    Mathieu, C.
    Franek, E.
    Philis-Tsimikas, A.
    Rose, L.
    Graungaard, T.
    Osterskov, A. B.
    Russell-Jones, D.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A29 - A29
  • [47] Investigating the safety and glycaemic control of fast-acting insulin aspart with a closed-loop delivery system in adults with type 1 diabetes
    Russell, S. J.
    Balliro, C. A.
    Ekelund, M.
    El-Khatib, F.
    Graungaard, T.
    Jafri, R.
    Rathor, N.
    Sherwood, J.
    Damiano, E. R.
    [J]. DIABETOLOGIA, 2020, 63 (SUPPL 1) : S346 - S346
  • [48] A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes
    Tim Heise
    Thomas R. Pieber
    Thomas Danne
    Lars Erichsen
    Hanne Haahr
    [J]. Clinical Pharmacokinetics, 2017, 56 : 551 - 559
  • [49] Efficacy and Safety of Fast-Acting Insulin Aspart in Adults with T2D with Different Insulin Requirements
    Lane, Wendy
    Ekelund, Magnus
    Thorisdottir, Olof
    Jodar, Esteban
    Oviedo, Alejandra
    Rathor, Naveen
    Senior, Peter
    Sesti, Giorgio
    Franek, Edward
    [J]. DIABETES, 2020, 69
  • [50] INVESTIGATING THE SAFETY AND GLYCAEMIC CONTROL OF FAST-ACTING INSULIN ASPART WITH A CLOSED-LOOP DELIVERY SYSTEM IN ADULTS WITH TYPE 1 DIABETES
    Russell, S.
    Balliro, C.
    Ekelund, M.
    El-Khatib, F.
    Graungaard, T.
    Jafri, R.
    Rathor, N.
    Sherwood, J.
    Damiano, E.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A37 - A37
12345